Confirmed Attendees for RESI Boston September. Join them with the Early Bird Rate.

By Antoinette Lowre, Manager of Business Development, LSN

RESI Boston September will continue with our hybrid format of 1-day in person at the Boston Park Plaza, followed by 2-days of virtual partnering. Monday, September 18 will feature our Investor Panels (check them out here), along with entrepreneur workshops led by industry expert service providers, and our popular Innovator’s Pitch Challenge (IPC) sessions. All alongside one-on-one partnering meetings from 8am-5pm.

We’re expecting over 300 more investors and strategic partners interested in partnering with early-stage life science companies to join us. Below are the confirmed investor attendees who will be at RESI Boston, September 18-20.

CI-07272023

Click Here to See More Investors

In addition to the 300+ investors, we are anticipating 300+ startups looking to raise capital and find providers for services they may need.

CC-07272023

SAVE $300 on your registration with the Early Bird Rate, ending tomorrow Friday, July 28th. Register now to join the RESI community this fall! The registration options are as followed:

Standard 3-day
(Sept. 18-20)
Virtual 2-day
(Sept. 19-20)
STARTUP $1,695 $1,995 $995 $1,195
Add the Premier Package* to view the full investor profiles, including contact information.
SERVICE PROVIDER $2,195 $2,495 $1,295 $1,495
EXHIBITOR $4,390 $4,990 Includes Two 3-Day Standard Tickets (Value: $4,990) and an Exhibition Table (Sept. 18) View RESI Sponsorship Brochure

RESI-Boston-2023-September-1100px-w

Mastering the Art of Partnering: A Roadmap for Startup Success

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the competitive entrepreneurship landscape, startups often need help distinguishing themselves from the competition; they are in a race to stand out amongst the sea of meeting requests the partners receive. Investors and licensing partners continuously lament the need for startups to develop concise, cogent, and compelling messaging that nets out their value proposition and sheds some light on the team and technology.

The problem lies in the cookie-cutter, problem-solution, market-oriented pitch decks that often fail to convey a strong personal narrative and compelling story. A startup must realize it is essentially a numbers game when they embark on a global partnering initiative. They must engage in dialogue with hundreds of potential partners to find the few that will participate in the round.  To start the dialogue, you need to secure a constant flow of meetings with partners who fit your stage of development and product. Therein lies the rub, how does a startup generate a pipeline of meetings with the right players?

Crafting a Compelling Story

Startup founders must recognize that potential investors and licensing partners invest in people before they invest in products or services. Startups must recognize the immense importance of weaving a compelling story that captivates the hearts and minds of potential partners. They should build a strong personal narrative highlighting their passion and vision. This narrative should highlight the founder’s journey, the team’s expertise, and the milestones achieved, backed by validated data. A strong personal narrative resonates with investors and partners, setting the foundation for a meaningful relationship.

Knowing Your Target Audience

In the dynamic world of entrepreneurship, understanding the target audience is key to crafting an effective brand message. Entrepreneurs must identify the ten categories of investors and licensing partners that align with their stage of development and product. Tailoring the pitch and messaging to cater to potential partners’ specific needs and interests significantly increases the chances of securing valuable meetings and partnerships. A concise tagline and compelling elevator pitch enable investors to assess the startup’s value proposition swiftly, paving the way for further engagement.

Making it Easy to Say Yes

A key principle of business development is making it easy for potential partners to say yes to a meeting. Startups should proactively present the “value add” of their founder, team, and technology. Anticipating and addressing potential partner needs and concerns demonstrates professionalism and builds trust. By providing researched, relevant information, startups improve their chances of moving forward in the partnering process.

Embrace the Global Arena

Founders must recognize that staying in their geographic regions limits the number of opportunities, thus hindering the number of partners to engage with. Breaking free from geographic limitations opens the startup to wider opportunities. Expanding globally requires a strategic game plan and sufficient resources to execute a global campaign and roadshow. Adopting and understanding rudimentary sales and marketing tactics, such as identifying potential partners and establishing a meeting pipeline, is essential to achieving success on an international scale.

Patience and Persistence

Partnering is a journey that demands both patience and persistence. The partnering process is not an overnight success story. It often takes between 9 to 18 months to establish successful partnerships. Startup teams should be prepared for the ebb and flow of partner meetings while maintaining an ongoing pipeline. A dedicated staff member focused on scheduling meetings with potential partners and utilizing a Customer Relationship Management (CRM) system to track and manage the target list can help keep the process on track. LSN has just announced a Global Campaign Management product integrating the LSN partnering database with the Salesforce CRM.

Mastering the art of partnering is a critical aspect of startup success. Entrepreneurs can significantly enhance their chances of securing essential partnerships by developing a compelling storyline, understanding their target audience, expanding from regional to global, and dedicating resources to meeting engagement. Above all, patience and persistence are vital traits needed to navigate a successful global partnering campaign.

RESI-Boston-2023-September-1100px-w

 Clinials + LSN Educational Workshop = RESI Innovator’s Pitch Challenge Success

Maree-BeareMaree Beare Interview with Maree Beare, Founder at Clinials

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiCaitlin Dolegowski

Maree Beare, Founder at Clinials, is a sector leader in HealthTec, FemTech and BioTech innovation. In 2021, Maree launched her second innovation, a BioTech company Clinials. Clinials is an AI-Driven clinical trial participant recruitment platform based in Brisbane, Australia, and a member of BEDA (Brisbane Economic Development Agency). Maree speaks with us about being a part of BEDA’s MedTech Accelerator cohort and her introduction to Life Science Nation followed by her eventual second-place finish in the Innovator’s Pitch Challenge at RESI Boston June earlier this summer.

RESI-Boston-2023-September-1100px-w

Hot Investor Mandate: USA-Based VC Invests in Early-Stage Therapeutics, Devices, and Diagnostics Companies Globally, Seeking Promising Assets With Strong IP in Place

A venture capital firm that was founded in 2020 with general partners based in the USA has a $100M USD fund dedicated to early-stage life science ventures from Seed to Series A.  The initial size of investment ranges from $1-5M and the firm seeks to invest in up to 10-12 early-stage life science companies worldwide.

The firm operates under a model that differs from traditional venture capital. As a way of de-risking, the firm works closely with a CRO that provides services and guidance on clinical translation and regulatory approval to therapeutics and medical device portfolio companies. The firm also works very closely with founders. As a critical criterion, the firm prefers to assign a highly experienced CEO to their portfolio company as they strongly believe in the importance of the management team. Also, the firm mostly exits through licensing to large pharma, medtech, or services companies. They are opportunistic about other exit strategies such as IPO.

The firm focuses on therapeutics, diagnostics, and digital health. The firm will not consider digital health. For therapeutics, pre-IND products of all modalities are considered. Within diagnostics, all modalities with proof of concept are considered. The firm will consider opportunities in any indication area.

The firm prefers asset-centric products and focuses on the scientific merits of the product or technology. The firm has a strict vetting process done by a highly experienced team and prefers companies with IP in place. The firm acts as a lead and co-investor and will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Early-Stage Evergreen Fund Seeks Medical Devices and Research Tools, Focusing on USA-Based Opportunities

An early-stage investment and development firm located in the US has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Invests in Innovative Medical Devices that Address Large Market Opportunities, Open to All Regulatory Pathways

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a fund focused on medtech investments. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Seeks Pre-Clinical Therapeutics Opportunities, With Particular Interest in Immunology and Oncology

An investor and venture builder invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in immunology and oncology. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe, and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.